-
Security Type
-
Crowd SAFE
-
Min Investment
-
$300
-
Offering Date
-
June 24, 2024
-
Expected Close Date
-
December 20, 2024
-
Target Raise
-
$50.00K-$618.00K
-
No. Investors
-
239
-
Security Price
-
$1
- Number of Employees
- 4
- Cash
- $3,277
- Revenue
- $0
- Short Term Debt
- $116
- Cost of Goods
- $0
- Long Term Debt
- $0
- Net Income
- $3,111
Company Description
Modern medicine has a measurement for almost every critical function in our body - cholesterol, glucose, blood pressure, heart function, lung capacity.
Yet when a patient walks into a doctors office suffering from persistent digestive issues, it’s still a guessing game. A patient might be told to take an antacid, handed a stronger prescription version, encouraged to try probiotics, or simply to “change your diet”.
The reality is doctors don’t have a good way to identify the root cause of the problem, leaving patients frustrated and conditions unresolved.
It’s a condition medically known as Dysbiosis, an unhealthy imbalance in the gut microbiome. Tens of millions suffer from it unknowingly.
Key Deal Facts
Innovative Science: 2 Platform Technologies from The University of Chicago
Experienced Leadership and Strong Team: Former J&J and Abbott Executives
Three Scientific Founders: Gut Microbiome World Experts
Differentiation and Competitive Advantage: Category Defining Technologies
Large Market Opportunities: $19.4B Total Available Market and Growing
Peak Year Sales Projection: $6.8B Platform Technologies Lead Indications
Strategy: Reduce Risk, Increase Reward, Create Investor Exit Optionality
Management Team / Advisory Board Bios
Peter Farmakis
CEO, Board Member
Brian Yoor
Board Member
Jaime Contreras
Board Member
Patrick Hennessey
EVP, Chief Business and Strategy Officer
Dr. John Alverdy
Scientific Founder
Dr. Eugene Chang
Scientific Founder
Joseph Pierre
Scientific Founder